© 1995 by Oxford University Press
Journal of the National Cancer Institute, Vol. 87, No. 20, 1546-1551,
October 18, 1995
© 1995 Oxford University Press
Effect of Matrix Metalloproteinase Inhibitor Batimastat on Breast Cancer Regrowth and Metastasis in Athymic Mice
Department of Medicine, Indiana University School of Medicine, and the Richard L. Roudebush VA Medical Center Indianapolis, Oxford, U.K.
Department of Medicine Oxford, U.K.
Department of Surgery, Indiana University School of Medicine Oxford, U.K.
British Biotech Pharmaceuticals, Ltd. Oxford, U.K.
*Correspondence to: George W. Sledge, Jr., M.D., Indiana University Hospital, Rm. 1730, 550 N. University Blvd., Indianapolis, IN 46202.
BACKGROUND:: Matrix metalloproteinases (MMPs) are involved in the invasion and metastasis of human cancers by mediating the degradation of extracellular matrix components. Therefore, these enzymes constitute promising targets in the development of anticancer therapies. Batimastat ([{4-N-hydroxyamino}-2R-isobuty1–3S-{thieny1-thiomethy1}succiny1]-L-phenyl-alanine-N-methylamide) is one of a new class of agents designed to inhibit MMP activity.
PURPOSE:: We asked whether batimastat, given as adjuvant therapy after primary tumor resection, could inhibit local-regional tumor regrowth and the formation of lung metastases in a human breast cancer xenograft model. We also explored possible effects of batimastat on breast cancer cell viability and on the accumulation of specific messenger RNAs (mRNAs).
METHODS:: Human MDA-MB-435 breast cancer cells were treated in vitro for 6 days with batimastat at concentrations ranging from 0.1 to 10.0 µM, and then viable cell counts were performed. The activity of collagenases, directly associated with cultured MDA-MB-435 cells or released into their culture fluids, was assessed by gelatin zymography after 1 and 3 days of batimastat treatment (drug range, 0.2–2.0 µM). Athymic nude mice were given daily intraperitoneal injections of batimastat (30 mg/kg body weight) after resection of MDA-MB-435 primary tumors grown in their mammary fat pads; the volumes of tumor regrowths and the numbers and volumes of lung metastases were calculated; neovascularization in the regrowths was assessed by immunohistochemical analysis with an antibody directed against CD31, an endothelial cell antigen. The effect of batimastat treatment on the accumulation of mRNAs encoding specific MMPs and the tissue inhibitor of metalloproteinases-2 (TIMP-2) in cultured cells, primary tumors, and tumor regrowths was measured by RNA dot blotting and hybridization with complementary probes. Linear regression analysis, Student's tests, and chi-squared analysis were used to evaluate the data.
RESULTS:: The viability of cultured MDA-MB-435 cells was not affected by treatment with batimastat; however, measured activities for the 72-kd and 92-kd collagenases released by these cells were reduced after batimastat treatment. Intraperitoneal injection of batimastat significantly inhibited the local-regional regrowth of resected MDA-MB-435 tumors in athymic nude mice (in comparison with control mice, P =.035), and it reduced the incidence (P<.05), number (P =.0001), and total volume (P =.0001) of lung metastases. Batimastat treatment did not affect cellular levels of MMP or TIMP-2 mRNAs.
CONCLUSION:: Batimastat inhibits human breast cancer regrowth and metastasis in a nude mouse xenograft model. Potential mechanisms for batimastat's inhibitory activity do not include direct cell toxicity or alteration of MMP or TIMP mRNA levels. [J Natl Cancer Inst 1995; 87: 1546–50]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Alonso-Escolano, C. Medina, K. Cieslik, A. Radomski, P. Jurasz, M. J. Santos-Martinez, T. Jiffar, P. Ruvolo, and M. W. Radomski Protein Kinase C{delta} Mediates Platelet-Induced Breast Cancer Cell Invasion J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 373 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Sparano, P. Bernardo, P. Stephenson, W. J. Gradishar, J. N. Ingle, S. Zucker, and N. E. Davidson Randomized Phase III Trial of Marimastat Versus Placebo in Patients With Metastatic Breast Cancer Who Have Responding or Stable Disease After First-Line Chemotherapy: Eastern Cooperative Oncology Group Trial E2196 J. Clin. Oncol., December 1, 2004; 22(23): 4683 - 4690. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-H. Yoon, Y.-J. Jung, T.-D. Kim, G. Li, B.-J. Park, J.-Y. Kim, Y.-C. Lee, J.-M. Kim, J.-I. Park, H.-D. Park, et al. Gabexate Mesilate Inhibits Colon Cancer Growth, Invasion, and Metastasis by Reducing Matrix Metalloproteinases and Angiogenesis Clin. Cancer Res., July 1, 2004; 10(13): 4517 - 4526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. D. Miller, T. J. Saphner, D. M. Waterhouse, T.-T. Chen, A. Rush-Taylor, J. A. Sparano, A. C. Wolff, M. A. Cobleigh, S. Galbraith, and G. W. Sledge A Randomized Phase II Feasibility Trial of BMS-275291 in Patients with Early Stage Breast Cancer Clin. Cancer Res., March 15, 2004; 10(6): 1971 - 1975. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Fowlkes, D. M. Serra, R. C. Bunn, K. M. Thrailkill, J. J. Enghild, and H. Nagase Regulation of Insulin-Like Growth Factor (IGF)-I Action by Matrix Metalloproteinase-3 Involves Selective Disruption of IGF-I/IGF-Binding Protein-3 Complexes Endocrinology, February 1, 2004; 145(2): 620 - 626. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kumar, H. Kishimoto, H. L. Chua, S. Badve, K. D. Miller, R. M. Bigsby, and H. Nakshatri Interleukin-1{alpha} Promotes Tumor Growth and Cachexia in MCF-7 Xenograft Model of Breast Cancer Am. J. Pathol., December 1, 2003; 163(6): 2531 - 2541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. D. Miller, W. Gradishar, L. Schuchter, J. A. Sparano, M. Cobleigh, N. Robert, H. Rasmussen, and G. W. Sledge A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer Ann. Onc., August 1, 2002; 13(8): 1220 - 1224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Coussens, B. Fingleton, and L. M. Matrisian Matrix Metalloproteinase Inhibitors and Cancer--Trials and Tribulations Science, March 29, 2002; 295(5564): 2387 - 2392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Hoekstra, F.A.L.M. Eskens, and J. Verweij Matrix Metalloproteinase Inhibitors: Current Developments and Future Perspectives Oncologist, October 1, 2001; 6(5): 415 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Johnston, J. B.M. Mullen, M. E. Pagura, and R. B. Howard Validation of an orthotopic model of human lung cancer with regional and systemic metastases Ann. Thorac. Surg., April 1, 2001; 71(4): 1120 - 1125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Zorzet, A. Bergamo, M. Cocchietto, A. Sorc, B. Gava, E. Alessio, E. Iengo, and G. Sava Lack of In Vitro Cytotoxicity, Associated to Increased G2-M Cell Fraction and Inhibition of Matrigel Invasion, May Predict In Vivo-Selective Antimetastasis Activity of Ruthenium Complexes J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 927 - 933. [Abstract] [Full Text]
|
|
|
|
|
|
E. Sunami, N. Tsuno, T. Osada, S. Saito, J. Kitayama, S. Tomozawa, T. Tsuruo, Y. Shibata, T. Muto, and H. Nagawa MMP-1 is a Prognostic Marker for Hematogenous Metastasis of Colorectal Cancer Oncologist, April 1, 2000; 5(2): 108 - 114. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. A. Bunn Jr., A. Soriano, G. Johnson, and L. Heasley New Therapeutic Strategies for Lung Cancer : Biology and Molecular Biology Come of Age Chest, April 1, 2000; 117 (2009): 163S - 168S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Nelson, B. Fingleton, M. L. Rothenberg, and L. M. Matrisian Matrix Metalloproteinases: Biologic Activity and Clinical Implications J. Clin. Oncol., March 1, 2000; 18(5): 1135 - 1135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Mitsiades, V. Poulaki, A. Leone, and M. Tsokos Fas-Mediated Apoptosis in Ewing's Sarcoma Cell Lines by Metalloproteinase Inhibitors J Natl Cancer Inst, October 6, 1999; 91(19): 1678 - 1684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. M. Macaulay, K. J. O'Byrne, M. P. Saunders, J. P. Braybrooke, L. Long, F. Gleeson, C. S. Mason, A. L. Harris, P. Brown, and D. C. Talbot Phase I Study of Intrapleural Batimastat (BB-94), a Matrix Metalloproteinase Inhibitor, in the Treatment of Malignant Pleural Effusions Clin. Cancer Res., March 1, 1999; 5(3): 513 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G I Murray, M E Duncan, E Arbuckle, W T Melvin, and J E Fothergill Matrix metalloproteinases and their inhibitors in gastric cancer Gut, December 1, 1998; 43(6): 791 - 797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.S. Fife and G.W. Sledge JR Effects of Doxycycline on Cancer Cells in Vitro and in Vivo Advances in Dental Research, November 1, 1998; 12(1): 94 - 96. [PDF]
|
|
|
|
|
|
B.L. Lokeshwar, H.L. Houston-Clark, M.G. Selzer, N.L. Block, and L.M. Golub Potential Application of a Chemically Modified Non-Antimicrobial Tetracycline (CMT-3) Against Metastatic Prostate Cancer Advances in Dental Research, November 1, 1998; 12(1): 97 - 102. [PDF]
|
|
|
|
 |
|
 T. H. Bugge, K. W. Kombrinck, Q. Xiao, K. Holmback, C. C. Daugherty, D. P. Witte, and J. L. Degen Growth and Dissemination of Lewis Lung Carcinoma in Plasminogen-Deficient Mice Blood, December 1, 1997; 90(11): 4522 - 4531. [Abstract] [Full Text] [PDF]
|
|